Aptorum To Start Testing SACT-1 In Neuroblastoma Patients

The FDA has signed off Aptorum Group Limited's APM IND application to initiate clinical trials of SACT-1 for neuroblastoma.
The IND-opening trial is a bioavailability/food effect study that will take four months to complete.
The bioavailability/food effect study aims to compare the relative bioavailability of the newly developed SACT-1 pediatric formulation in healthy adult subjects.
The above study will follow a planned Phase 1b/2a trial in pediatric patients with relapsed or refractory high-risk neuroblastoma.
SACT-1 is an orally administered repurposed small molecule drug designed to suppresses MYCN expression (a protein found in neuroblastoma patients).
SACT-1 is designed to be used especially in combination with standard-of-care chemotherapy.
Related content: Benzinga's Full FDA Calendar.
Price Action: APM shares are up 2.66% at $2.70 during the premarket session on the last check Wednesday.